Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

EyeBrain. (4/11/13). "Press Release: EyeBrain Launches an International Clinical Trial of Its Application for Dyslexia. EUR 220,000 of Backing from the EUREKA-Eurostars Program". Ivry-sur-Seine.

Region Region EU (European Union)
Organisations Organisation EyeBrain (FR)
  Organisation 2 University of Lübeck (Universität zu Lübeck, UzL)
Products Product diagnostic device
  Product 2 neurology
Person Person Schmitt-dos Santos, Juliette (Andrew Lloyd & Associates 2012– Director joined 2002)
     


EUR 220,000 of backing from the EUREKA-Eurostars program will help this trial evaluate whether the type of ocular motor dysfunction identified in Frenchspeaking dyslexic children is also found in English-speaking and Germanspeaking dyslexic children


EyeBrain, which develops markers of cerebral function for neurological and psychiatric conditions, today announces the launch of an international clinical trial of its application for dyslexia. The total cost of the program will be EUR 700,000.

The trial will include 120 French, 120 German and 120 English children aged between 6 and 15. It will validate the assessment of ocular motor function indicated by the results of the company's medical device and determine whether ocular motor dysfunction is the same in all these children, or whether it differs according to their mother tongue. The trial will be conducted at the Robert Debré hospital in Paris, France, in partnership with Inserm, the French national institute of health and medical research, and the University of Lübeck in Germany. EyeBrain is in discussion with potential partners for the Englishspeaking component of the trial.

It is noticeable that dyslexia is less prevalent in populations which use a language with a 'transparent' orthography (where sounds and letters have a one-to-one relationship, i.e. one sound equals one letter and one letter equals one sound), such as Italian, than in populations which use a language with an 'opaque' orthography (where a variety of letters can be used to transcribe the same sound, and letters can be pronounced in different ways), such as English.

The application that EyeBrain has developed focuses on the measurement of ocular motor dysfunction in children whilst reading. It offers specialists a means of evaluating parameters of ocular motor function quickly and automatically when their patients are reading. In particular, it provides the ability to define binocular vision disorders in precise detail. A two-minute ocular motor examination will enable the detailed qualification of
specific parameters of ocular motor function in reading. This may help improve early detection of these disorders.

EyeBrain has received a total of EUR 220,000 in EUREKA-Eurostar subsidies for this trial. EUREKA is a European intergovernmental program, working to promote R&D cooperation between European businesses, in a case-by-case collaboration with research institutes. Through the program, SMEs can obtain a label certifying the quality of the project, and access funding for their collaborative Research, Development and Innovation (RDI) projects. In turn, developed by both EUREKA and the European Commission, the Eurostars program aims to support innovative, market-oriented SMEs with strong growth potential and involvement in European collaborative projects. The program's primary targets are businesses that are investing heavily in R&D.

Following completion of the trial at the end of 2015, EyeBrain plans to market English and German language add-ons to its application for evaluating ocular motor function in children with reading disabilities. The application that EyeBrain has developed will therefore be available in three languages, French, English and German.

"This trial means that EyeBrain can create new markets with its application for assessing ocular motor function in reading disabilities," said Serge Kinkingnéhun, CEO of EyeBrain. "We are seeing real professional interest in this approach. As things stand, there is no system for evaluating and quantifying patients' disabilities in a strictly numerical way. Our approach makes this possible."

Under normal circumstances, children have learned to read after two years of primary schooling. A disability is defined as a lag of at least 18 months between actual age and reading age.

The percentage of dyslexics in the global population is generally estimated at around 5%, with figures varying from 3 to 10% or up to as much as 12%, depending on the criteria used to define dyslexia (for example, whether assessment of the child's reading level includes consideration of their intellectual level), and the type of orthography used in the language of the population in question. Around 5% of German-speaking children, 6 to 8% of French-speaking children and up to 15% of English-speaking children are dyslexic (1).


(1) Data on prevalence. In Expertise collective Inserm. Dyslexia, dysorthographia and dyscalculia. Scientific data (pp. 175-190). Paris: Les éditions Inserm, 2007.


About EyeBrain

EyeBrain is developing brain function markers for neurological and psychiatric diseases utilizing devices based on eye motricity. They make it possible to test specific regions of the brain by recording and analyzing eye movements using very sophisticated algorithms developed by the company. The devices developed by EyeBrain have filled a void in the devices used in neurology; they complete a standard clinical examination within 20 minutes and at a lower cost than imaging techniques (MRI, scanners). They are also noninvasive relative to other types of examination in standard use (lumbar punctures, blood tests).

The EyeBrain Tracker (EBT) devices come as a complete package that includes an eyetracker, a chin rest, two screens and a computer, together with stimulation and analysis software. When used routinely in hospital, they already provide the doctor with information for the early characterization of Parkinsonian syndromes (AMS, PSP, CBD, etc.), for monitoring multiple sclerosis and for dyslexia. The EBTs are the only devices of this type to have obtained CE marking, while EyeBrain also has ISO 9001 and ISO 13485 certification. Eye motricity testing (eye tracking) is paid for by the French social security system.

EyeBrain, which was founded in 2008, is based in the Paris suburb of Ivry-sur-Seine and currently employs 12 people. The company raised 1.2 million euros from CapDecisif Management and G1JIDF in an initial funding round in 2009, and 3.3 million euros from Octalfa, Sudinnova and CM-CIC Capital Innovation in a second round in 2012. EyeBrain generates revenues from the sale of its tracker device. It is engaged in collaborations with the French National Institute of Health and Medical Research (Inserm), the French National Scientific Research Center (CNRS), the Paris Public Hospital Authority (AP-HP) and the University of Paris-Descartes. EyeBrain also has premises within the Brain and Spinal Cord Institute of the Pitié-Salpêtrière hospital in Paris, which is a world-class research center.

For further information, go to: http://www.eye-brain.com -
http://www.eyebrainpedia.com


Contact media and analysts

Andrew Lloyd & Associates
Juliette dos Santos - Neil Hunter
juliette@ala.com - neil@ala.com
Tel : + 44 1273 675 100

   
Record changed: 2016-01-10

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top